RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma

Withdrawn before enrolling · Not applicable

Conditions studied: Renal Cell Carcinoma

In brief

The purpose of this study is to look at the effects of a procedure called radiofrequency ablation on kidney tumors from patients who are undergoing antiangiogenic treatment. Antiangiogenic treatment is a type of treatment that inhibits formation of new blood vessels that are required for tumor growth. Radiofrequency ablation (RF ablation) involves inserting a needle into tumor tissue and administering heat to the tumor tissue that is sufficient to kill the tumor cells.

Key facts

Study ID

NCT00601120

Run by

Beth Israel Deaconess Medical Center

People needed

0

Starts

2007-06-01

Last updated by the study team

2013-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who are on antiangiogenic therapy for a minimum of 4 weeks and have isolated metastatic lesions showing either persistence or resistance to therapy that might benefit from local therapy such as RF ablation.
• Male or female patients 18 years of age or older
• Clinical, radiographic, or pathologic diagnosis of clear cell RCC
• Ongoing treatment with sorafenib or sunitinib, off clinical trials
• Acceptable risk for general anesthesia in the judgement of the study investigator and by the department of anesthesiology upon preoperative testing.
• At least one lesion that has not completely resolved while on antiangiogenic therapy
• Candidate lesions of 1cm or greater in diameter
• Safe access to the tumor for a needle placed under ultrasound guidance
• ECOG Performance Status of 0 or 1
• Adequate bone marrow, and renal as assessed by the laboratory requirements outlined in the protocol

You may not qualify if…

• History of bleeding diathesis or unexpected surgical bleeding
• Patients currently on anticoagulation
• Medical contraindication to MR imaging (pacemaker, metal debris in eye, etc.)
• Prior RF to the index tumor
• Pregnant or lactating

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.